Robust Angio-Vasculogenic Properties of 3D-Cultured Dual GCP-2/PDGF-β Gene-Edited Human ASCs

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Angiogenesis Research

Background:

• Adipose-derived mesenchymal stem cells (ASCs) show promise for regenerative medicine.
• Therapeutic efficacy of ASCs is limited by poor microenvironments in damaged tissues.
• Enhancing ASC function for tissue repair is crucial.

Purpose of the Study:

• To genetically engineer ASCs to express granulocyte chemotactic protein-2 (GCP-2) and platelet-derived growth factor-β (PDGF-β).
• To evaluate the proangiogenic potential of these modified ASCs in a 3D culture system.
• To assess the therapeutic efficacy of these engineered ASCs in a hind limb ischemia model.

Main Methods:

• Genetic modification of ASCs to overexpress GCP-2 and PDGF-β.
• Three-dimensional (3D) cell culture of engineered ASCs (3D-A/GP).
• In vitro assays for cell migration and endothelial tube formation.
• Matrigel plug assay to assess in vivo angiogenesis.
• Hind limb ischemia (HLI) mouse model to evaluate therapeutic effects.

Main Results:

• 3D-cultured ASCs overexpressing GCP-2 and PDGF-β (3D-A/GP) showed increased proangiogenic gene expression, cell migration, and endothelial tube formation.
• 3D-A/GP formed functional blood vessels in Matrigel plugs.
• In the HLI model, 3D-A/GP injection led to improved blood flow recovery, limb salvage, capillary density, and reduced apoptosis.
• Engineered ASCs differentiated into endothelial-like cells and upregulated angiogenic factors in ischemic tissue.

Conclusions:

• Combining genetic engineering (GCP-2 and PDGF-β overexpression) with 3D culture enhances ASC therapeutic potential for angiogenesis-dependent tissue repair.
• This dual approach offers a synergistic strategy to improve ASC-based therapies for ischemic diseases.
• The engineered ASCs demonstrate significant potential for regenerative medicine applications.